BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8279839)

  • 1. [State of the art of drug therapy in breast cancer].
    Watanabe T
    Gan To Kagaku Ryoho; 1993 Dec; 20(16):2437-46. PubMed ID: 8279839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant therapy for breast cancer.
    NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
    National Institutes of Health Consensus Development Panel
    J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Dose density and dose intensity in the treatment of breast cancer].
    Saintigny P; Assouad S; Gligorov J; Selle F; Roché H; Breau JL; Morère JF; Lotz JP
    Bull Cancer; 2004 Dec; 91 Suppl 4():S244-53. PubMed ID: 15899616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Studies with high-dose chemotherapy and subsequent autologous stem cell transplantation in breast carcinoma].
    Nitz U; Adomeit A; Mohrmann S; Fossari A; Frick M
    Praxis (Bern 1994); 1998 Apr; 87(17):578-83. PubMed ID: 9623324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose therapy for breast cancer.
    Hudis CA; Münster PN
    Semin Oncol; 1999 Feb; 26(1):35-47. PubMed ID: 10073560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer in the elderly.
    Crivellari D; Aapro M; Leonard R; von Minckwitz G; Brain E; Goldhirsch A; Veronesi A; Muss H
    J Clin Oncol; 2007 May; 25(14):1882-90. PubMed ID: 17488987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous bone marrow transplantation in the treatment of breast cancer: clinical and technologic strategies.
    Vaughan WP
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):55-8. PubMed ID: 8211216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
    Ingle JN
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant treatment of high-risk stage II breast cancer with doxorubicin followed by high-dose chemotherapy and autologous stem-cell transplantation: a single-institution experience with 132 consecutive patients.
    Stemmer SM; Hardan I; Raz H; Adamou AK; Inbar M; Gottfried M; Merrick Y; Cohen Y; Sulkes A; Ben-Baruch N; Pfeffer RP; Brenner HJ; Rizel S
    Bone Marrow Transplant; 2003 Apr; 31(8):655-61. PubMed ID: 12692605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
    Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E
    Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose therapy in breast cancer: out of favor but not out of promise.
    Glück S; Stewart D
    Bone Marrow Transplant; 2000 May; 25(10):1017-9. PubMed ID: 10828859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant therapy of breast cancer.
    Kaklamani VG; Gradishar WJ
    Cancer Invest; 2005; 23(6):548-60. PubMed ID: 16203663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined modality approach for high-risk breast cancer. The Milan Cancer Institute experience.
    Bonadonna G; Valagussa P
    Surg Oncol Clin N Am; 1995 Oct; 4(4):701-14. PubMed ID: 8535906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future status of adjuvant therapy for breast cancer.
    Coleman RE
    Cancer; 2003 Feb; 97(3 Suppl):880-6. PubMed ID: 12548590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current trends in pharmacotherapy of breast cancer].
    Boér K
    Orv Hetil; 2002 Apr; 143(14):725-30. PubMed ID: 11975393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Special issues related to breast cancer adjuvant therapy in older women.
    Witherby SM; Muss HB
    Breast; 2005 Dec; 14(6):600-11. PubMed ID: 16198568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
    Poole R; Paridaens R
    Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin in combination therapy for metastatic breast cancer.
    Perez EA
    Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.